GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
TrustPilot
哈立德 Z.
1 周前
Sneha T.
1 个月前
Anjali K.
尤素夫·A.
